The National Institute for Health and Clinical Excellence (NICE) is set to do a u-turn on its decision earlier this year to deny patients with wet AMD access to Lucentis.
NICE had stipulated that Lucentis should be used for people with predominantly 'classic subfoveal choroidal neovascularisation' and only when both eyes were affected. It advised that the eye with best vision should receive the drug. The guidance recommended the use of Lucentis for about 20 per cent of patients with wet AMD.
However, according a report in the Daily Telegraph as Optician went to press, NICE is set to abolish the 'second eye' stipulation in new draft guidelines due to be published today (Friday) and widen availability.
Register now to continue reading
Thank you for visiting Optician Online. Register now to access up to 10 news and opinion articles a month.
Register
Already have an account? Sign in here